Results 161 to 170 of about 3,775 (204)
Value in Health, 2013 ObjectivesFidaxomicin is a novel treatment for Clostridium difficile infections (CDIs). This new treatment, however, is associated with a higher acquisition cost compared with alternatives.
Paul M Stranges +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2011
Fidaxomicin is a first-in-class macrocyclic antibacterial that primarily demonstrates activity against species of clostridia, predominantly Clostridium difficile, while having limited or no activity against normal faecal microflora. Fidaxomicin is minimally absorbed following oral administration and is excreted almost solely in the faeces.
J. Cada Dennis +2 more
openaire +3 more sources
Fidaxomicin is a first-in-class macrocyclic antibacterial that primarily demonstrates activity against species of clostridia, predominantly Clostridium difficile, while having limited or no activity against normal faecal microflora. Fidaxomicin is minimally absorbed following oral administration and is excreted almost solely in the faeces.
J. Cada Dennis +2 more
openaire +3 more sources
Anaerobe, 2015 The aim of this study was to investigate in vitro activities of fidaxomicin and other antibiotics against 188 Clostridium difficile strains collected from different centers of Hungary. C.
Gabriella Terhes +2 more
exaly +2 more sources
Fidaxomicin: Balancing evidence and economics
American Journal of Health-System Pharmacy, 2012Over the past 10 years, Clostridium difficile infection (CDI) has become a leading cause of nosocomial infection and a significant source of health care expenditures in the United States. The standard therapies for CDI—oral vancomycin and metronidazole—are both associated with significant ...
Vanessa, Stevens +2 more
openaire +2 more sources
Probable fidaxomicin-induced pancytopenia
American Journal of Health-System Pharmacy, 2018A case of pancytopenia in a patient receiving treatment with fidaxomicin for Clostridium difficile infection (CDI) is described.A 33-year-old Caucasian woman was admitted to the hospital with a chief complaint of loose stools occurring approximately 7 times a day; she also reported fever, nausea, diffuse abdominal pain, and fatigue.
Samantha, Axtell +2 more
openaire +2 more sources
Clarifications about add-on payments for fidaxomicin
American Journal of Health-System Pharmacy, 2013The efforts of AJHP, through a news article,[1][1] to educate a pharmacy audience about the new technology add-on payment (NTAP) for fidaxomicin tablets are to be commended. We wish to provide clarification and update readers about recent developments.
Hemal, Shah +2 more
openaire +2 more sources
Fidaxomicin: first-in-class macrocyclic antibiotic
Expert Review of Anti-infective Therapy, 2011The incidence of Clostridium difficile has doubled over the past 15 years, and rising mortality rates associated with this infection have followed in its wake. C. difficile infection (CDI) has supplanted methicillin-resistant Staphylococcus aureus as the major cause of nosocomial infection.
Kathleen M, Mullane, Sherwood, Gorbach
openaire +2 more sources
Fidaxomicin for the Treatment of Clostridium diffìcile Infections
Annals of Pharmacotherapy, 2012Objective: To evaluate the pharmacology, microbiology, safety, and efficacy of fidaxomicin for treatment of Clostridium difficile infections (CDI). Data Sources: Literature was identified through Ovid MEDLINE (1940-December 2011) and ...
Craig B, Whitman, Quinn A, Czosnowski
openaire +2 more sources